Product Data Sheet

K-Ras G12C-IN-4

 Cat. No.:
 HY-128771

 CAS No.:
 2376328-55-9

 Molecular Formula:
 C₃₁H₃₃ClN₄O₄

 Molecular Weight:
 561.07

Pathway: GPCR/G Protein

Storage: Powder -20°C 3 years

Ras

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

Target:

DMSO: 62.5 mg/mL (111.39 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.7823 mL	8.9115 mL	17.8231 mL
	5 mM	0.3565 mL	1.7823 mL	3.5646 mL
	10 mM	0.1782 mL	0.8912 mL	1.7823 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: 2.08 mg/mL (3.71 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS ^{G12C[1]} .
In Vitro	K-Ras G12C-IN-4 (4 hours) exhibits IC_{50} =0.219 μ M for inhibition of MAPK signaling (p-ERK) in MIA PaCa-2 cells ^[1] . K-Ras G12C-IN-4 (72 hours) translates to a 0.067 μ M IC ₅₀ for inhibition of cellular viability in a CellTiter-Glo experiment in MIA PaCa-2 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

1]. Shin Y, et al. Discovery of N-	(1-Acryloylazetidin-3-yl)-2-(1	LH-indol-1-yl)acetamides as Cov	alent Inhibitors of KRASG12C. ACS Med	Chem Lett. 2019 Aug 20;10(9):1302-1308
	Caution: Product has n	at been fully validated for m	edical applications. For research ι	uco only
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpr	
			outh Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com